Indication | Percentage of sites eligible to perform split protocol for this indication (n = 77) |
Head and neck cancer | 55.8 |
Melanoma | 10.4 |
Thyroid cancer | 7.8 |
Radiotherapy planning | 6.5 |
Lung cancer | 3.9 |
Breast cancer | 2.6 |
CT contrast study | 2.6 |
Brain tumors | 2.6 |
Other tumors | 7.8 |